Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Docetaxel in Advanced Esophageal Squamous Cell Carcinoma
NCT03193424Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2016
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-Free Survival at 6 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03193424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193424.